PXMTF (PHAXIAM Therapeutics) General and Admin. Expense: $4.58 Mil (TTM As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics General and Admin. Expense?

PHAXIAM Therapeutics PXMTF 38 General and Admin. Expense is $4.58 Mil as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. PHAXIAM Therapeutics's General and Admin. Expense for the three months ended in Sep. 2023 was $3.16 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 was $4.58 Mil.

PHAXIAM Therapeutics General and Admin. Expense Related Terms

PHAXIAM Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics General and Admin. Expense Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.01 18.24 16.08 15.79 12.94

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 3.76 1.42 0.00 3.16
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $4.58 Mil mean?
PHAXIAM Therapeutics (PXMTF) has a General and Admin. Expense of $4.58 Mil as of Sep. 2023. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' General and Admin. Expense too high?
PHAXIAM Therapeutics' current General and Admin. Expense is $4.58 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' General and Admin. Expense compare to VRTX and REGN?
PHAXIAM Therapeutics' General and Admin. Expense of $4.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current General and Admin. Expense is $4.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current General and Admin. Expense of $4.58 Mil. The current General and Admin. Expense is $4.58 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current General and Admin. Expense is $4.58 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price